BCL2 and acute myeloid leukemia: Combining Venetoclax (Ven), a selective BCL-2 inhibitor, with HMAs or LDAC yields high response rates and durable remission, with a good safety profile, in patients with AML who are ineligible for intensive chemotherapy (3–5).